Dendreon Crosses Fingers, Knocks on Wood, And Resubmits Provenge To FDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Dendreon resubmitted its prostate cancer treatment Provenge (sipuleucel-T) to FDA Nov. 2, two and a half years after the agency disagreed with an advisory panel and rejected the vaccine, which targets metastatic, castration-resistant forms of the disease.